Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University of Wuerzburg |
---|---|
Information provided by: | University of Wuerzburg |
ClinicalTrials.gov Identifier: | NCT00311337 |
Protocol DSMM VIII is a multi-center, open-label study evaluating the safety and tolerability, as well as the efficacy, of maintenance treatment with VELCADE (bortezomib) in patients with multiple myeloma with detectable disease activity following tandem high-dose chemotherapy and autologous SCT. The time from SCT to the initiation of VELCADE treatment will be 3 to 6 months.
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma |
Drug: bortezomib |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study |
Official Title: | Evaluation of Safety and Efficacy of VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following High-Dose Melphalan Treatment and Autologous PBSCT (Minimal Residual Disease, Partial Remission or Stable Disease) |
Estimated Enrollment: | 61 |
Study Start Date: | October 2005 |
Estimated Study Completion Date: | October 2010 |
Protocol DSMM VIII is a multi-center, open-label study evaluating the safety and tolerability, as well as the efficacy, of maintenance treatment with VELCADE in patients with multiple myeloma with detectable disease activity following tandem high-dose chemotherapy and autologous SCT. The time from SCT to the initiation of VELCADE treatment will be 3 to 6 months. The initial 11 patients entered into this trial will be treated at a dose level of 1.0 mg/m2 once weekly on 4 consecutive weeks followed by 2 weeks of rest. A total of 4 treatment cycles is planned. An interim analysis for safety and tolerability will be performed after at least the first cycle of study drug has been completed. If the study treatment is found to be safe and no dose-limiting toxicity has occurred, the dose of VELCADE will be increased to 1.3 mg/m2 and another 11 patients will be treated at this dose level according to the treatment schedule as outlined above. The dose escalation to 1.3 mg/m2 will be performed without delay if no AE or SAE are reported to the principal investigator. If the safety of a specific dose level is acceptable the efficacy of the maintenance treatment will be statistically evaluated. The treatment is considered to be efficacious if a minimum of 25% of all treated patients experience a success, considered as remission of their disease within 6 months after the end of VELCADE treatment. The therapy will be acceptable for further clinical studies if a minium of 25% successfully treated patients will be observed. Under these assumptions in the first step of the optimal two step design (Simon 1989) 21 patients have to be treated. As patients included during phase I are included in the efficacy analysis, this means an additional 10 patients to be treated. If less than three patients were successfully treated defined as an improvement in the remission status, the study will be stopped, because the success rate is unacceptably low. If three or more of the 21 patients are successfully treated, another 29 patients will be included. At the end of the study the success rate will be evaluated. If 8 or more of the 50 patients were successfully treated the therapy will be acceptable for further studies.
Patients will be evaluated at scheduled screening and baseline visits. After providing written informed consent to participate in the study, patients will be screened for study eligibility during a screening period of 28 days. Baseline assessment consists of a detailed history of pre-existing diseases, blood tests including disease-specific markers such as ß2-microglobulin, IgG, IgA, IgM, immunofixation from blood and urine, serum free light chains, a bone marrow biopsy, a skeletal survey, an electrocardiogram and a chest X-ray. The study drug will be administered in study centers only. Prior to each administration of study drug, a short medical history focusing on VELCADE-associated side effects will be performed as well as complete blood cell counts, kidney and liver function tests.
A visit on day 30 following the last administration of study drug for the final assessment of safety and tolerability is mandatory in all patients included in this protocol. Serological myeloma specific markers (monoclonal immunoglobulin, serum free light chains and immunofixation from blood and urine) will be performed at weeks 6, 12, 18 and 24 and thereafter in 3 months intervals. Bone marrow biopsies will be performed when serological markers indicate complete remission or progression, a skeletal survey once a year during follow-up. During the study, disease will be assessed according to the EBMT/IBMTR/ABMTR criteria. Safety will be evaluated by the occurrence of clinical and laboratory toxicities and changes from baseline in physical examination findings, vital signs, and, if applicable, chest X-ray and electrocardiogram findings. All patients will receive an aminobisphosphonate at 4 weekly intervals. Other disease-modifying treatment such as alpha interferon or pulsed corticosteroids are strictly prohibited.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Hermann Einsele, MD | +49-931-20170011 | einsele_h@klinik.uni-wuerzburg.de |
Contact: Holger Hebart, MD | +49 7071 2984477 | hrhebart@med.uni-tuebingen.de |
Austria | |
Medizinische Univ.-Klinik Graz | Recruiting |
Graz, Austria, 8036 | |
Contact: Werner Linkesch, MD ++43(0)316/385-4086 werner.linkesch@kfunigraz.ac | |
Principal Investigator: Werner Linkesch, MD | |
Klin. Abt. für Onkologie, AKH Wien | Recruiting |
Vienna, Austria, 1090 | |
Contact: Johannes Drach, MD heinz.gisslinger@akh-wien.ac.at | |
Principal Investigator: Johannes Drach, MD | |
Germany | |
Dept. of Internal Medicine, Ludwig-Maximilian-University Munich | Recruiting |
Munich, Germany, 80336 | |
Contact: Christian Straka, MD 089/5160-2278 cstraka@medinn.med.uni-muenchen.de | |
Principal Investigator: Christian Straka, MD | |
Dept. of Hematology/Oncology, Charité Berlin | Recruiting |
Berlin, Germany, 10098 | |
Contact: Orhan Sezer, MD 030/450-513105 sezer@charite.de | |
Principal Investigator: Orhan Sezer, MD | |
Dept. of Internal Medicine III, University of Ulm | Recruiting |
Ulm, Germany, 89081 | |
Contact: Peter Liebisch, MD 0731/500-33809 peter.liebisch@medizin.uni-ulm.de | |
Principal Investigator: Peter Liebisch, MD | |
Dept. of Internal Medicine A, University Muenster | Recruiting |
Muenster, Germany, 48129 | |
Contact: Martin Kropff, MD kropff@uni-muenster.de | |
Sub-Investigator: Martin Kropff, MD | |
Dept. of Internal Medicine II, University of Wuerzburg | Recruiting |
Wuerzburg, Germany, 97070 | |
Contact: Hermann Einsele, MD +4993120170011 einsele_h@klinik.uni-wuerzburg.de | |
Sub-Investigator: Volker Kunzmann, MD | |
Sub-Investigator: Stefan Knop, MD | |
Italy | |
Regionalkrankenhaus Bozen | Recruiting |
Bozen, Italy, 39100 | |
Contact: Paolo Coser, MD 0039/471/908807 emat@asbz.it | |
Principal Investigator: Paolo Coser, MD |
Principal Investigator: | Hermann Einsele, MD | Dept. of Internal Medicine II, University of Wuerzburg, Klinikstr. 6-8, 97070 Wuerzburg |
Principal Investigator: | Hermann Einsele, MD | Dept. of Internal Medicine, University of Wuerzburg |
Study ID Numbers: | DSMM VIII |
Study First Received: | April 3, 2006 |
Last Updated: | April 4, 2006 |
ClinicalTrials.gov Identifier: | NCT00311337 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
VELCADE bortezomib maintenance treatment multiple myeloma primary disease |
Neoplasm, Residual Melphalan Immunoproliferative Disorders Blood Protein Disorders Hematologic Diseases Blood Coagulation Disorders Bortezomib Vascular Diseases |
Paraproteinemias Hemostatic Disorders Protease Inhibitors Multiple Myeloma Hemorrhagic Disorders Lymphoproliferative Disorders Neoplasms, Plasma Cell |
Neoplasms by Histologic Type Immunoproliferative Disorders Molecular Mechanisms of Pharmacological Action Immune System Diseases Antineoplastic Agents Blood Protein Disorders Hematologic Diseases Bortezomib Vascular Diseases Enzyme Inhibitors Paraproteinemias |
Hemostatic Disorders Pharmacologic Actions Protease Inhibitors Multiple Myeloma Neoplasms Hemorrhagic Disorders Therapeutic Uses Cardiovascular Diseases Lymphoproliferative Disorders Neoplasms, Plasma Cell |